

d) the corresponding complement of sequences a), b), or c).

4 19. (New) An isolated composition comprising a first component selected from a group consisting of physiologically acceptable carriers and immunostimulants, and a second component comprising a polypeptide according to claim 18.

sub 32 20. (New) A diagnostic kit comprising at least one oligonucleotide that hybridizes to SEQ ID NO: 301, under moderately stringent conditions.


#### REMARKS

Following the above amendment, claims 3, 4, and 18-20 are under consideration. Claims 1, 8, 11 and 15 have been cancelled. Claim 3 has been amended. Claims 18-20 have been added. Applicants submit that newly added claims 18-20 are within the scope of elected Group I.

Consideration of the elected claims is now requested. Please credit any overpayment or charge any deficiency to Deposit Account Number 19-1090.

Respectfully submitted,

Seed Intellectual Property Law Group PLLC

  
\_\_\_\_\_  
Jeffrey Hundley, Ph.D., Patent Agent  
Registration No. 42.676

JEH:sds

Enclosure:

Postcard

701 Fifth Avenue, Suite 6300  
Seattle, Washington 98104-7092  
(206) 622-4900  
Fax: (206) 682-6031

D:\NPortbl\Manage\SHARONS 260811-1.DOC